AI assistant
Biotest AG Board/Management Information 2025
66_rns_2025-03-06_c0de586a-910e-496d-9ddf-b653f3c74869.html
Board/Management Information
Open in viewerOpens in your device viewer
News Details
Ad-hoc | 6 March 2025 09:01
Biotest AG: CFO Martin Möller to leave Biotest as planned at the end of his contract. Position of CFO to be filled in the near future.
Biotest AG / Key word(s): Personnel
Biotest AG: CFO Martin Möller to leave Biotest as planned at the end of his contract. Position of CFO to be filled in the near future.
06-March-2025 / 09:01 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.
**Ad hoc NOTICE
Notification pursuant to Art. 17 EU Market Abuse Regulation (MAR)**
CFO Martin Möller to leave Biotest as planned at the end of his contract. Position of CFO to be filled in the near future
Dreieich, Germany, 6 March 2025. The Board of Management of Biotest AG announces that Chief Financial Officer Martin Möller will terminate his position as CFO as planned at the end of his contract expires on 15 March 2025.
The Supervisory Board has already initiated the search for a suitable successor and aims to fill the position in the near future.
Martin Möller will continue to support Biotest AG in an advisory capacity beyond the end of his contract.
Biotest Aktiengesellschaft
The Board of Management
Biotest AG
Landsteinerstr. 5
D-63303 Dreieich
www.biotest.com
Disclaimer
This document contains forward-looking statements on the overall economic development and the business, earnings, financial and asset situation of Biotest AG and its subsidiaries. These statements are based on the company’s current plans, estimates, forecasts and expectations and are therefore subject to risks and uncertainties that could cause actual developments to differ materially from those anticipated. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and does not assume any obligation to do so.
About Biotest
Biotest (www.biotest.com) is a provider of biological therapeutics derived from human plasma. With a value-added chain that extends from preclinical and clinical development to worldwide sales, Biotest has specialized primarily in the areas of clinical immunology, hematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and hematopoietic systems. Biotest has more than 2,500 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German Stock Exchange. Since May 2022, Biotest has been a part of the Grifols Group, headquartered in Barcelona, Spain ( www.grifols.com ).
IR contact
Dr Monika Baumann (Buttkereit)
Phone: +49-6103-801-4406
Mail: [email protected]
PR contact
Dirk Neumüller
Phone: +49-6103-801-269
Mail: [email protected]
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com
Ordinary shares: securities’ ID No. 522720; ISIN DE0005227201
Preference shares: securities’ ID No. 522723; ISIN DE0005227235
Listing: Frankfurt (Prime Standard)
Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate
Contact:
Martin Möller
Chief Financial Officer
Biotest AG
Landsteinerstr. 5
63303 Dreieich
Tel. +40 6103 801 2999
Fax: +49 6103 801 767
End of Inside Information
06-March-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
| Language: | English |
| Company: | Biotest AG |
| Landsteinerstraße 5 | |
| 63303 Dreieich | |
| Germany | |
| Phone: | 0 61 03 – 8 01-0 |
| Fax: | 0 61 03 – 8 01-767 |
| E-mail: | [email protected] |
| Internet: | www.biotest.com |
| ISIN: | DE0005227235, DE0005227201 |
| WKN: | 522723, 522720 |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 2096222 |
| End of Announcement | EQS News Service |
2096222 06-March-2025 CET/CEST